The centrifugal ventricular assist device (CVAD) was developed for long-term circulatory support, and is capable of either intracorporeal implantation or paracorporeal placement. The pump was designed based on our antithrombogenic concepts: (1) sealless pump casing, (2) elimination of stationary parts, and (3) blood flow acceleration under the impeller. To meet conditions (1) and (2), a pivot bearing system was adopted to support the impeller. The inlet port was placed slightly off-center and inclined 60 towards the same direction as the outlet port. This port configuration not only yielded a space where an inlet cup bearing could be directly embedded but also allowed for a significant reduction of the pump height, hence, resulting in easier placement inside the body cavity. Two small secondary vanes were installed in the bottom of the impeller to satisfy condition (3). Five paracorporeal left ventricular (LV) AD studies, using calves, were performed to evaluate the antithrombogenic design of the pump. The first two cases were subjected to 2-week tests. With the activated clotting time (ACT) kept at 250 s with heparin, the initial two cases had trouble-free performances over the 2 weeks. Following these successful results, another three cases were subjected to 1-month validation studies, in which there was no device-induced thrombus formation inside the pump housing. These results confirm that the CVAD, the C1E3, meets the requirements for a 1-month paracorporeal LVAD.
Free Download Body Pump 77
2ff7e9595c
Comentarios